Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Scientists Find New Drug Target for Hard-to-Treat Leukaemia

Published: Friday, March 30, 2012
Last Updated: Friday, March 30, 2012
Bookmark and Share
Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival.

The team at the Paterson Institute for Cancer Research at The University of Manchester have identified a new drug target – an enzyme called LSD1 – for an aggressive form of acute myeloid leukaemia called mixed lineage leukaemia (MLL).  LSD1 helps control whether certain cancer-causing genes are turned on or off. Blocking the enzyme prevents the production of proteins that drive the cancer.

Scientists at Cancer Research UK’s Paterson Drug Discovery Unit synthesised molecules to block this enzyme, and lead author Dr Tim Somervaille, group leader at Cancer Research UK’s Leukaemia Biology Laboratory, showed that they could stop the growth of leukaemia cells – taken from patients with the disease, and also from mice.

Every year in the UK around 2,380 people are diagnosed with acute myeloid leukaemia and of these it is estimated that around five percent – around 120 patients – have the MLL subtype.
Survival for acute myeloid leukaemia remains low although it has improved. Currently, around forty percent of people aged under 60 with the MLL-AF9 subtype survive the disease for five years or more.

Dr Somervaille said: “It’s difficult to successfully treat patients with this type of leukaemia. There aren’t any targeted drugs available and many patients can’t be cured with current treatments, such as intensive chemotherapy and bone marrow transplantation.  So there’s an urgent need for new drugs.

“We’re very pleased to have tested molecules that homes in on an enzyme called LSD1 in a completely new approach to stop the growth of this disease. And we also believe this target may be important in a range of other types of cancer, but more research is needed.

“The next stage is to develop molecules like this one further, and run clinical trials to see if they could be used to treat patients in the future.”

Dr Julie Sharp, Cancer Research UK’s senior science information manager, said: “It’s great news that this molecule could provide a new targeted way to treat an aggressive type of leukaemia, for which treatment options are limited.

“Our scientists have been at the heart of progress that has seen great improvements in the treatment of leukaemia. For example, we developed some of the first important drugs for blood cancers and pioneered treatment with radiotherapy. And we’ve revealed many of the gene changes that fuel the development and growth of blood cancers, paving the way for future treatments.

“But there is much more to be done and, only with continued public support, can our scientists around the UK continue their groundbreaking research into leukaemia to learn more about the biology of the disease – and improve survival.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

‘Liquid Biopsies’ Could Help Spot Genetic Faults in Lung Cancer
Study analyze blood samples from 97 patients who took part in the EURTAC clinical trial.
Saturday, March 07, 2015
New Companies Join Cancer Research UK Consortium
Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia.
Thursday, December 11, 2014
Why Bowel Cancer Sometimes Outsmarts Treatment
New study challenges the prevailing view of how bowel cancer develops in the large intestine.
Tuesday, December 02, 2014
Cancer Cell Fingerprints in the Blood May Speed up Childhood Cancer Diagnosis
Researchers found unique molecular fingerprints for 11 types of children’s tumours, to develop blood tests to diagnose these cancers.
Tuesday, November 04, 2014
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner
Partnership Developed to Trial Immunotherapy Vaccine For Lung Cancer
Friday, September 12, 2014
Cancer Research UK, Astellas Partner on Cancer Treatments
The new collaboration will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.
Friday, August 08, 2014
New Route to Boost Pancreatic Cancer Treatment
Cancer Research UK scientists have uncovered new insights into how the key pancreatic cancer drug gemcitabine is broken down in tumour cells.
Monday, June 02, 2014
Cancer Research UK, AZ and Pfizer Partner to Advance Lung Cancer Treatment
Partnership creates a pioneering clinical trial for patients with advanced lung cancer, marking a new era of research into personalised medicines to treat cancer.
Thursday, April 17, 2014
Final Results from the Phase III TeloVac Trial in Pancreatic Cancer
Results from the trial showed no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy.
Tuesday, June 04, 2013
Astronomy Algorithms Help Diagnose Aggressive Tumors
Scientists have honed techniques originally developed to spot distant galaxies and used them to identify biomarkers that signal a cancer’s aggressiveness among some 2,000 breast tumours.
Monday, February 25, 2013
Study Points to Potential New Treatment for Deadly Pancreatic Cancer
Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.
Tuesday, May 01, 2012
Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates
Eden Biodesign to provide process development and manufacturing services for two of CR-UK’s gene therapy products for head and neck cancer.
Thursday, September 06, 2007
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Oxitec ‘Self-Limiting Gene’ Offers Hope for Controlling Invasive Moth
A new pesticide-free and environmentally-friendly way to control insect pests has moved ahead with the publication of results showing that Oxitec diamondback moths (DBM) with a ‘self-limiting gene’ can dramatically reduce populations of DBM.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
Kiwi Bird Genome Sequenced
The kiwi, national symbol of New Zealand, gives insights into the evolution of nocturnal animals.
Scientists Identify Schizophrenia’s “Rosetta Stone” Gene
Scientists have identified a critical function of what they believe to be schizophrenia’s “Rosetta Stone” gene that could hold the key to decoding the function of all genes involved in the disease.
Yeast Cells Use Signaling Pathway to Modify Their Genomes
Researchers at the Babraham Institute and Cambridge Systems Biology Centre, University of Cambridge have shown that yeast can modify their genomes to take advantage of an excess of calories in the environment and attain optimal growth.
Nanoparticles Can Clean Up Environmental Pollutants
Researchers have found that nanomaterials and UV light can “trap” chemicals for easy removal from soil and water.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!